These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27794060)

  • 1. Deranged Liver Function in a Neonate.
    Peake RW
    Clin Chem; 2016 Nov; 62(11):1539-1541. PubMed ID: 27794060
    [No Abstract]   [Full Text] [Related]  

  • 2. Neonatal screening for hereditary tyrosinaemia: are we there yet?
    Hadžić N; Vara R
    Arch Dis Child; 2015 Aug; 100(8):720-1. PubMed ID: 25957320
    [No Abstract]   [Full Text] [Related]  

  • 3. Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.
    Rashed MS; Al-Ahaidib LY; Al-Dirbashi OY; Al Amoudi M; Al-Sayed MM; Rahbeeni Z; Al-Hassnan Z; Al-Dbaas A; Al-Owain M; Ni Luanaigh M
    Anal Biochem; 2005 Apr; 339(2):310-7. PubMed ID: 15797572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of children with hereditary tyrosinaemia following newborn screening.
    McKiernan PJ; Preece MA; Chakrapani A
    Arch Dis Child; 2015 Aug; 100(8):738-41. PubMed ID: 25564536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Québec NTBC Study.
    ; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
    Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids.
    Al-Dirbashi OY; Fisher L; McRoberts C; Siriwardena K; Geraghty M; Chakraborty P
    Clin Biochem; 2010 May; 43(7-8):691-3. PubMed ID: 19836366
    [No Abstract]   [Full Text] [Related]  

  • 7. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 1 Tyrosinaemia.
    Mannion MA; Smith A; Mayne P; Monavari AA
    Ir Med J; 2016 Jun; 109(6):426. PubMed ID: 27814443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
    Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
    Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H; Iwai M; Taniuchi Y; Katashima M; Takahashi H
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126
    [No Abstract]   [Full Text] [Related]  

  • 11. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug to treat rare pediatric liver disease.
    FDA Consum; 2002; 36(2):5. PubMed ID: 11989476
    [No Abstract]   [Full Text] [Related]  

  • 13. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
    Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
    Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
    Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancing newborn screening for tyrosinemia type I.
    Pass KA; Morrissey M
    Clin Chem; 2008 Apr; 54(4):627-9. PubMed ID: 18375485
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
    Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the management of tyrosinaemia type 1.
    de Laet C; Dionisi-Vici C; Leonard JV; McKiernan P; Mitchell G; Monti L; de Baulny HO; Pintos-Morell G; Spiekerkötter U
    Orphanet J Rare Dis; 2013 Jan; 8():8. PubMed ID: 23311542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
    László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
    Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs; nitisinone].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2541-2. PubMed ID: 17152330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.